A Phase 2 interventional study of GSK4532990 and Placebo in Liver Diseases, Alcoholic, sponsored by GlaxoSmithKline. Recruiting at 150 sites in 19 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Liver Diseases, Alcoholic with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Liver Diseases, Alcoholic · United States.
Among the 23 studies in Liver Diseases, Alcoholic with a site in United States, this one has the largest planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2024, is one of 5 in phase 2, and was the 22nd registered.
74 studies on the registry are indexed under Liver Diseases, Alcoholic; 25 are open to participants now.
Browse Liver Diseases, Alcoholic studies →7 of the 23 studies in Liver Diseases, Alcoholic with a site in United States are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States, Argentina, Canada and 1 more country
Ages 18–75
The Cleveland Clinic · Sites in United States
Ages 21+
The Cleveland Clinic · Sites in United States
Ages 18–75 · Healthy volunteers
Nicole T Shen · Sites in United States
Ages 18–80
The Cleveland Clinic · Sites in United States
Ages 18–65 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Liver Diseases, Alcoholic studies recruiting now, 7 (39%) set no upper age limit and 7 (39%) stop at 75 or younger; none take children under 18; 4 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 2
First in 2003; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 350 is above the median of 90 across 44 interventional studies indexed under Liver Diseases, Alcoholic.
Median enrollment 41 across the 16 interventional studies, 160 across the 7 observational. Of the 13 that completed or were terminated, 4 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 23 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 2 studies filed under Liver Diseases, Alcoholic — fewer than ten, so there is no comparison to draw.
2 of the studies in Liver Diseases, Alcoholic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03224949The Cleveland ClinicComparison of ALD, NASH, and Healthy Control Patients | 2027-09-30 |
| NCT06613698GlaxoSmithKlineA Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease | 2027-11-26 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies in Liver Diseases, Alcoholic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to assess the safety and efficacy of GSK4532990 in participants with alcohol-related liver disease.
The criteria were revised on the registry on Nov 13, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: GSK4532990
Drug: GSK4532990
Drug: GSK4532990
Drug: GSK4532990
Drug: Placebo
GSK4532990 will be administered
Placebo will be administered
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Time frame: Up to 8 weeks
Number of participants with potentially clinically relevant changes in electrocardiogram (ECG), vital signs, and clinical laboratory tests.
Time frame: Up to 8 weeks
Change from baseline in Liver Stiffness measurement (LSM) reduction using FibroScan® at Week 52 (kiloPascal)
Liver stiffness will be measured by vibration-controlled transient elastography (VCTE) using the FibroScan® device.
Time frame: Baseline (Day 1) and at Week 52
Maximum plasma concentration (Cmax) of GSK4532990
Time frame: Up to Day 4
Area Under the Curve from Time 0 to t [AUC (0-t)] of GSK4532990
Time frame: Up to Day 4
Area Under the Curve from Time 0 to 24 hours [AUC (0-24)] of GSK4532990
Time frame: Up to 24 hours
Plasma half-life (t1/2) of GSK4532990
Time frame: Up to Day 4
Apparent clearance (CL/F) of GSK4532990
Time frame: Up to Day 4
Time to maximum concentration (tmax) of GSK4532990
Time frame: Up to Day 4
Apparent terminal phase volume of distribution (Vz/F) of GSK4532990
Time frame: Up to Day 4
Change from baseline in serum AST at Week 52
Time frame: Baseline (Day 1), and at Week 52
Change from baseline in Enhanced Liver Fibrosis (ELFTM) score at Week 52
The ELFTM score will be calculated using a published algorithm combining the values of a set of extracellular matrix markers, including tissue inhibitor of metalloproteinases-1 (TIMP-1), type III procollagen (PIIINP), and hyaluronic acid (HA). The ELFTM score is used as a prognostic marker for disease progression. ELFTM score will range between 4.5 to 14.7. A higher ELFTM score will predict worse prognosis
Time frame: Baseline (Day 1), and at Week 52
Change from baseline in model for end-stage liver disease (MELD) score at Week 52
MELD is a scoring system for assessing the severity of chronic liver disease. MELD scores range between 6 and 40, with 40 being the most severe.
Time frame: Baseline (Day 1), and at Week 52
Change from baseline in LSM using FibroScan® at Week 52 (kiloPascal)
Time frame: Baseline (Day 1), and at Week 52
Area under the concentration-time curve from time zero (pre-dose) to the last quantifiable concentration (AUC0-t) of GSK4532990
Time frame: Up to Day 3
Maximum observed plasma concentration (Cmax) of GSK4532990
Time frame: Up to Day 3
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Showing the first 100 of 150 sites across 19 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk-studyregister.com
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Nov 2027, 37 months after the start.
Completion moved once since we started tracking on Sep 25, 2026: Mar 2028 → Mar 2029, on Nov 13, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GSK4532990